Cambridge, UK based Healx, an AI powered rare disease company, announced a $47M series C financing today
Co-founder and CEO Tim Guilliams describes the investors who led the round and how it will allow Healx to advance its lead program for neurofibromatosis Type 1 into a phase 2 study.